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ABSTRACT 
Several studies have reported decreased platelet 5-HT uptake in patients of major 
depression. The mechanism of antidepressant action of ECT is not clear. The present work was 
undertaken with the aim to study the active platelet 5-HT uptake and the effect of ECT on it in 
patients of major depression. 15 patients of major depression (DSM-lll-R) and equal number of 
age and sex-matched controls were included in the study. Active platelet 5-HT uptake was deter-
mined before ECT, after a course of ECT and 7 days after last ECT. Platelet 5-HT uptake was. 
significantly lower in der essives than normal controls. After ECT treatment there was significant 
increase in 5-HT uptake which came down to pretreatment level after 1 week of last ECT. The 
effect of ECT on serotonergic system is discussed. 
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Dysfunction of brain serotonergic 
system may be a factor responsible for mood 
and behavioural disturbances associated with 
depression. Major depression, or at least a 
subcategory thereof, is thought to be 
associated with disturbances in the serotonin 
(5-HT) system as indicated by, for example, 
low cerebrospinal fluid concentrations of the 
5-HT metabolite 5-hydroxy indoleacetic acid 
(Asberg et al., 1984). Studies showing a low 
5-HT uptake (Vmax) into blood platelets 
(Tuomisto et al., 1976; Coopen et al., 1978; 
Meltzeret al., 1981; Malmgren et al., 1981), a 
low number of 3H-impramine binding sites 
(Bmax) in platelets (Briley et al., 1980; A'sarch 
et al., 1980; Paul et al., 1981; Wagner et al., 
1985) and a low concentration of 5-HT in 
platelets or whole blood (Coppen et al., 1976; 
LeGuen et al., 1984; Sarrias et al., 1987) also 
support this assumption. 
Platelet serotonin measures represent 
indirect but easily obtainable indices of brain 
serotonin function (Sheline et al., 1995). The 
human platelet 5-HT2 receptor may resemble 
a peripheral model of central 5-HT2 binding sites 
and has been linked by changes in 5-HT2 re-
ceptor function in depression (Steckler et al., 
1993). Several studies have reported decreased 
platelet 5-HT uptake in depressed patients 
(Hallstrom et al., 1976; Scott et al., 1979; 
Ehsanullah, 1990; Born et al., 1980; Jeffery et 
al., 1982). 
The mechanism of antidepressant action 
of electroconvulsive therapy (ECT) is still a 
matter of controversy. Shapira et al. (1992) 
showed that ECT enhances central 
serotonergic responsivity. Subramanyam (1975) 
reported that ECT produced a sustained 
increase in the synthesis and turn over of 
amines in the brain. Jori et al. (1975) reported 
that ECT caused significant increase in CSF 
5-HIAA at the time of recovery than at the 
beginning of the treatment. Costainetal. (1979) 
reported that ECT potentiates 5-HT effects in 
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test animals (rats). 
The present study was undertaken with 
the aim to find out active platelet 5-HT uptake 
in depressed patients and effect of ECT in these 
patients. 
MATERIAL & METHOD 
Subjects for the study consisted of a 
depressive group and a control group. All 
consecutive drug-naive patients of depression 
of both sexes between 17-60 years admitted in 
the Department of Psychiatry, K.G.'s Medical 
College, Lucknow were screened. DSM-III-R 
criteria (APA, 1987) was used forthe diagnosis 
of major depression (single episode or recur-
rent). Hamilton Rating Scale for Depression 
(Hamilton, 1960) was used to rate the severity 
of depression and those patients scoring 17 
points or more on 17-item scale were included 
in the study. Exclusion criteria were presence 
of physical illness requiring active medication, 
papilledema, epilepsy, mental retardation, or-
ganic brain syndrome, pregnancy, and drug 
and/or alcohol dependence. 
Control group comprised of normal 
healthy volunteers matched for age and sex 
with depressives. Controls were screened on 
Cornell Medical Index (CMI) (Brodman et al., 
1949) and those who gave thirty or more "yes" 
responses on entire CMI and/or ten or more 
"yes" responses on M-R sections of CMI were 
excluded. Controls with past or family history 
of depression were also excluded. Other 
exclusion criteria were same as for the 
depressive group. 
All the subjects included in the study were 
kept drug free except tablet lorazepam on s.o.s 
basis because antidepressants or antipsychot-
ics may alter platelet 5-HT uptake (Todrick & 
Tait, 1969; Boullin et al., 1978). The subjects 
were kept on a diet free of pineapples, bananas, 
plums and nuts forthe entire duration of study. 
Controls were also kept on a similar dietary 
restriction for a period of 7 days before taking 
blood sample. This specific restriction on the 
diet was imposed especially for tryptophan 
containing food items as tryptophan, a precur-
sor of 5-hydroxytryptamine (5-HT), could have 
altered the levels of 5-HT and its metabolites 
in serum and CSF (Wurtman & Fernstrom, 
1974; Sneddon, 1973; Knott & Curson, 1972), 
thus altering the results. 
The depressives were given only 
modified electroconvulsive therapy, first three 
on alternate days and on every fourth day 
thereafter to a maximum of ten by the end of 
five weeks treatment phase. Subsequently, all 
depressives were kept free of ECT or drug for 
7 days after last ECT. Atropine (1 mg IV) was 
administered two minutes before the 
anaesthetic medication. Thiopental (2-3 mg/kg 
body weight IV) was used as the anaesthetic 
agent and succinylcholine (0.5-1.0 mg/kg body 
weight IV) as muscle relaxant. Sine wave ECT 
was administered by "Electrocon" Model 
manufactured by associated electronic 
engineers, Bangalore, using bitemporal 
electrodes. 90 to 120 volt electrical stimulus for 
0.5-1.0 seconds was given to induce 
seizures. 
Seventy of depression and response to 
ECT was assessed on Hamilton Rating Scale 
for depression (HRSD) which was administered 
on the day of hospitalization and then at weekly 
interval till the end of the treatment phase (day 
35 or when HRSD sore fell below 5 points) and 
7 days after last ECT. 
Routine haemogram, SGOT, serum 
bilirubin, serum creatinine, serum proteins, 
blood urea, blood sugar, urine examination and 
bilateral fundus oculi examination were done 
in all subjects and those with abnormal test 
results were excluded. For platelet 5-HT uptake 
estimation, subjects were kept overnight 
fasting and in the morning (between 8 to 9 a.m.) 
10 ml. venous blood was drawn by a dispos-
able syringe rinsed with 3.8% sodium citrate and 
transferred into polypropylene tube containing 
1 ml. of 3.8% sodium citrate as anticoagulant 
(Born & Cross, 1963; Mills & Robert, 1967). 
Blood samples were drawn in fasting condition 
in the morning (Meltzeret al., 1981) to control 
forthe diurnal rhythm of platelet 5-HT uptake. 
The sample tubes were immediately (within one 
hour) sent to Industrial Toxicology Research 
Centre, Lucknow for assessment. 
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The platelet 5-HT uptake was estimated 
by following the principles of the method de-
scribed by Scott et al. (1979). The counting was 
done in a liquid scintillation counter (LKB 
wallac). In order to assess the active uptake, 
the passive uptake was substracted from the 
total uptake. The data is represented in terms 
of picomoles of
 3H (tritiated) 5-HT uptaken/10
8 
platelets/5 minutes. 
For depressives the platelet 5-HT uptake 
estimation was done prior to starting the 
treatment, at the end of ECT treatment and 7 
days after last ECT. For controls only one 
sample was estimated. 
Student's T test was used to find the level 
of significance between two mean values. 
Paired "t" test was used to determine the level 
of significance of mean of difference where the 
observations were paired. Pearson's product 
moment correlation coefficient was used to 
measure the degree of association between two 
series ot observations. 
RESULTS 
The sample for the study consisted of 15 
patients of major depression and equal number 
of age and sex-matched controls. Mean age of 
depressives and controls was 43.93 (range 25-
56) and 42.60 (range 26-54) years respectively 
and there was no significant difference between 
the two. There were 8 males and 7 females in 
each group. 
HRSD scores in depressives prior to 
treatment was 28.47± 4.41 which decreased 
significantly to 4.73±4.09 after treatment with 
ECT and this improvement remained nearly 
maintained after 7 days of last ECT (5.87±.80). 
Active platelet 5-HT uptake in 
depressives prior to treatment was 1,32±0.40 
(pmol/10
8 platelets/5min.). There was'no 
significant correlation between active platelet 
5-HT uptake and severity of depression (r=0. 
13;NS). There was also no significant 
difference in active platelet 5HT uptake between 
the subject with first episode depression and 
recurrent depression. 
Active platelet 5-HT uptake (in pmol/10
8 
platelets/5min) was significantly lower in 
depressives (1.32±0.42) as compared to 
controls (1.77±0.47) prior to treatment. After 
treatment with ECT, there was a significant 
increase in active platelet 5-HT uptake 
(1.97±0.38) from pretreatment levels but 7 days 
after last ECT the active platelet 5-HT uptake 
decreased to 1.35±0.38 which was nearly 
similar to pretreatment levels (table -1). Mean 
number of ECTs given to depressives was 
8.87+2.45. Percentage increase in active 
platelet 5-HT uptake after ECT's was 
47.06±34.71. 
DISCUSSION 
This study was undertaken with trie aim 
to study the active platelet 5-HT uptake in 
depressed patients and the effect of ECT on 
active platelet 5-HT uptake in these patients. 
The major finding of our study was that platelet 
5-HT uptake was lower in patients of major 
depression as compared to controls and ECT 
treatment resulted in increase in active platelet 
5-HT uptake. 
Pretreatment HRSD score in depressives 
was 28.47± 4.41. ECT successfully ameliorated 
the depressive symptoms with post treatment 
HRSD score being 4.73±4.09 and this clinical 
improvement was maintained after seven days 
of treatment free period (HRSD score 
5.87±4.80). The mean duration of treatment with 
ECT was 3.99 weeks. The response rate was 
82.77% which is in keeping with the 
reports that most of the depressives show good 
therapeutic response to ECT (Dubovsky, 1995). 
The uptake of 5-HT in both brain and 
blood platelet requires active uptake process 
against a considerable concentration gradient 
(Blackburn et al., 1967; Chase et al., 1969). The 
process of passive uptake of 5-HT in both brain 
and blood platelets is of little or no 
physiological importance, only contributing to 
uptake at high susbtrate concentrations and not 
influenced by drugs such as imipramine which 
block the active transport process (Fuke et al., 
1964). The 5-HT concentration in whole blood 
or platelets and the total 5-HT uptake (both 
active & passive) lack the specificity which the 
active platelet 5-HT uptake has and do not 
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TABLE 
COMPARISON OF ACTIVE PLATELET 5-HT UPTAKE 
IN DEPRlfSSlVES AND CONTROLS 
Group 
A. Controls (N=15) 
B. Pre-ECT(N=15) 
C. After a course of  ECT(N 













* Uptake values In picomoles of
 JH 5-HT uptake /10' 
platelets /5min 
A. vs. B t=2.82; df=28; p<01 
A vs. C t=1.28; df=28; NS 
A vs. D t=2.69; df=28; p,.05 
B vsC t=3.87; df=14;p<.01 
B vsD t=0.39; df=14;NS 
C vs.D t=5.44; df=14; p<.05 
parallel with the CNS parameters so closely as 
the active platelet 5-HT uptake does. Hence, 
active platelet 5-HT uptake was studied and 
for this the estimation was done at a low 
concentration of 5HT and for a short incubation 
period which is necessary for accurate results 
(Sneddon, 1973). 
Active platelet 5-HT uptake was 
significantly lower in depressed patients as 
compared to controls prior to treatment 
(table -1). Similar findings have been reported 
by Hallstrom et al. (1976), Scott et al. (1979), 
Ehsanullah (1980) and Born et al. (1980), 
However, Shaw et al. (1971) found no 
difference in the uptake of platelet 5-HT in 
depressed patients, but the excessive 
concentration of 5-HT and the long incubation 
time used in that study precluded accurate 
determination of active 5-HT. 
Lingjaerde (1983) hypothesized that there 
is a lowered turnover of 5-HT in at least a 
subgroup of depressed patients which is 
reflected in lowered concentration of 5-HIAA in 
the CSF or lowered concentration of 5-HT in 
blood or in platelet or lowered active 5-HT 
uptake in blood platelets of these patients 
(uptake can be taken as a reflection for 
turnover). Moreover, as platelet can be taken 
as neuronal model for 5-HT, it can be interpreted 
that akin to platelets, in the pre-synaptic 
neurons the active 5-HT uptake is lowered in 
depressed patients which may be a 
compensatory mechanism, the function of 
which is to "make the best" out of the reduced 
amount of 5-HT in the synaptic cleft. 
Treatment with ECT resulted in a 
significant increase in the active platelet 5-HT 
uptake (1.9 ± 38 pmol/10
8 platelets/5min) as 
compared to the pretreatment levels (1.32 ± 
0.40 pmol/10
8 platelets/5min) This increase in 
active platelet 5-HT uptake was higher than 
controls (1.77± 0.47) though statistically there 
was no significant difference between the two 
(table). This means that clinical improvement 
in depressive symptoms (i.e. HRSD score), 
after treatment with ECT corresponded with 
increase in active platelet 5-HT uptake. 
Although ECT is highly effective as 
short-term treatment for depression, 50 to 70% 
of nonpsychotically depressed patients and upto 
95% of psychotically depressed patients 
relapse, at least one half to four fifths of them 
in the first two to four months after the 
completion of therapy. The relapse rate is 
reduced to about 20% in patients maintained 
after ECT on antidepressants or lithium 
(Dubovsky, 1995). In the present study, the 
increase in active platelet 5-HT uptake after 
treatment with ECT reverted to nearly 
pretreatment levels after 7 days of treatment 
free period indicating a risk for relapse. This 
finding substantiates the need for maintenance 
treatment in depression even after clinical 
improvement in depressive symptoms has 
occurred. As stated earlier that uptake could 
be taken as a reflection for turnover, the 
findings of the present study suggest that ECT 
might increase the turnover of 5-HT in 
platelets. Gayford et al. (1973) found increased 
5-HT blood levels after ECT in depressed 
patients. Subramanyam (1975) reported that 
ECT produced sustained increase in 
synthesis, utilization and turnover of the amines 
in the brain of depressives. Jori et al. (1975) 
reported that ECT determined significant 
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increase in CSF 5-HIIA at the time of recovery 
than at the beginning of the treatment. Costain 
et al. (1979) found that ECT potentiates 5-HT 
effects in test animals (rats). Although no firm 
conclusions can be drawn, it is possible that by 
ECT increased turnover of 5-HT in blood 
platelets (findings of the present study), in blood 
(Gayford et al., 1973) and increased turnover 
of CSF 5-HIIA (Subramanyam, 1975; Jori et al., 
1975; Costain et al., 1979) may be relevant to 
the antidepressant activity of ECT. 
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